(RTTNews) - TransCode Therapeutics Inc. (RNAZ) announced publication in Cancer Nanotechnology of preclinical data supporting therapeutic potential of TTX-MC138(MN-anti-miR10b) in metastatic breast cancer.
In Thursday pre-market trade, RNAZ was trading at $3.09 up $0.47 or 17.94%.
The study confirmed the biodistribution of TTX-MC138 in models of metastatic cancer, supporting TransCode's TTX platform for delivery of RNA targeted therapy to metastatic solid tumors.
The company looks forward to its Phase 0 study which has the potential to establish clinical proof-of-concept for this therapy.
TransCode expects to file an exploratory investigational new drug (eIND) application for TTX-MC138 in the first quarter of 2022 to support a Phase 0 study in patients with metastatic cancer.
Under an eIND, FDA approval may be obtained more quickly and at lower cost than with a traditional IND for therapeutic agents.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.